Cargando…

Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling

PURPOSE: To understand and compare preferences for dosing- and toxicity-related attributes associated with selective cyclin-dependent 4/6 kinase inhibitors regimens among US oncologists and patients. MATERIALS AND METHODS: Oncologists and patients with mBC participated in an internet-based survey th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maculaitis, Martine C, Liu, Xianchen, Will, Oliver, Hanson, Madelyn, McRoy, Lynn, Berk, Alexandra, Crastnopol, Melissa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652230/ https://www.ncbi.nlm.nih.gov/pubmed/33177814 http://dx.doi.org/10.2147/PPA.S254934

Ejemplares similares

Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
por: Beusterien, Kathleen, et al.
Publicado: (2021)

Psychosocial Wellbeing among Patients with Breast Cancer during COVID-19
por: Maculaitis, Martine C., et al.
Publicado: (2023)

Chinese Consumers’ Preferences for Attributes of Fresh Milk: A Best–Worst Approach
por: Jin, Shaosheng, et al.
Publicado: (2019)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Most and least important attributes for domestic travel: A best-worst scaling approach
por: Lee, Soyeun Olivia, et al.
Publicado: (2022)

“It was the best of times, it was the worst of times”
por: Yu Chuan, Jack Li
Publicado: (2022)

Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment
por: Liu, Frank Xiaoqing, et al.
Publicado: (2017)

The Role of Trust in Explaining Food Choice: Combining Choice Experiment and Attribute Best–Worst Scaling †
por: Yeh, Ching-Hua, et al.
Publicado: (2020)

A Think Aloud Study Comparing the Validity and Acceptability of Discrete Choice and Best Worst Scaling Methods
por: Whitty, Jennifer A., et al.
Publicado: (2014)

What are colorectal cancer survivors’ preferences for dietary advice? A best-worst discrete choice experiment
por: Wright, Stuart J., et al.
Publicado: (2017)

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
por: DeMichele, Angela, et al.
Publicado: (2021)

The Best of Times and Yet the Worst of Times
por: Greear, Emma, et al.
Publicado: (2021)

Two for the price of one: If moving beyond traditional single‐best discrete choice experiments, should we use best‐worst, best‐best or ranking for preference elicitation?
por: Huls, Samare P. I., et al.
Publicado: (2022)

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018)

Testing Cessation Messages for Cigarette Package Inserts: Findings from a Best/Worst Discrete Choice Experiment
por: Thrasher, James F., et al.
Publicado: (2018)

Comparison of preferences of healthcare professionals and MS patients for attributes of disease‐modifying drugs: A best‐worst scaling
por: Kremer, Ingrid E. H., et al.
Publicado: (2017)

Developing an Assessment of Contraceptive Preferences in Botswana: Piloting a Novel Approach Using Best-Worst Scaling of Attributes
por: Gertz, Alida M., et al.
Publicado: (2022)

Prostate cancer survivors’ preferences on the delivery of diet and lifestyle advice: a pilot best-worst discrete choice experiment
por: Robles, Luke A., et al.
Publicado: (2020)

Comparing Outcomes of a Discrete Choice Experiment and Case 2 Best-Worst Scaling: An Application to Neuromuscular Disease Treatment
por: Soekhai, Vikas, et al.
Publicado: (2023)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Large Hadron Collider: Best- and worst-case scenarios
por: Madrigal , Alexis
Publicado: (2008)

Best-worst scaling improves measurement of first impressions
por: Burton, Nichola, et al.
Publicado: (2019)

COVID-19 brought out the best and worst of us
por: van Zyl-Smit, Richard
Publicado: (2022)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects
por: Le, Hannah, et al.
Publicado: (2021)

Assessment of patients’ preferences for new anticancer drugs in China: a best–worst discrete choice experiment on three common cancer types
por: Feng, Zhe, et al.
Publicado: (2023)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Using Best–Worst Scaling to Investigate Preferences in Health Care
por: Cheung, Kei Long, et al.
Publicado: (2016)

Discrete choice experiments or best-worst scaling? A qualitative study to determine the suitability of preference elicitation tasks in research with children and young people
por: Rogers, Helen J., et al.
Publicado: (2021)

HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
por: Sammons, Sarah L., et al.
Publicado: (2017)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Are We Prepared for the CDK4/6 Revolution With HR+/HER2− Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies
por: Azoz, Seyla, et al.
Publicado: (2023)

Prepare for the worst, plan for the best: disaster preparedness and recovery for small businesses
por: Childs, Donna R, et al.
Publicado: (2008)

Good boss, bad boss: how to be the best... and learn from the worst
por: Sutton, Robert I
Publicado: (2010)

Making the best of the worst: Care quality during emergency cesarean sections
por: Andersen, Betina Ristorp, et al.
Publicado: (2020)

Differential effects of changes in cardiorespiratory fitness on worst- and best- school subjects
por: Ishihara, Toru, et al.
Publicado: (2021)

Best–Worst Scaling and the Prioritization of Objects in Health: A Systematic Review
por: Hollin, Ilene L., et al.
Publicado: (2022)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Assessment of Patient Attribution to Care From Medical Oncologists, Surgeons, or Radiation Oncologists After Newly Diagnosed Cancer
por: Gondi, Suhas, et al.
Publicado: (2021)

Experimental measurement of preferences in health and healthcare using best-worst scaling: an overview
por: Mühlbacher, Axel C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_288t8tf3anbr463i28um2as3e7